1. Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma
- Author
-
Krasimira Aleksandrova, Jana Leise, Christoph Priesner, Murat Aktas, Michael Apel, Mario Assenmacher, Iris Bürger, Anne Richter, Pia Altefrohne, Christine Schubert, Astrid Holzinger, Markus Barden, Valerie Bezler, Michael von Bergwelt-Baildon, Peter Borchmann, Lilia Goudeva, Wolfgang Glienke, Lubomir Arseniev, Ruth Esser, Hinrich Abken, and Ulrike Koehl
- Subjects
clinical CD20 CAR T cell trial ,automated manufacturing of engineered T cell products ,ex vivo expansion ,cell composition of CAR T cell products ,CD20 CAR investigational medicinal product ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionPoint-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade. In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targeting a variety of tumor-associated epitopes.MethodsHere, we report the manufacturing and characterization of autologous anti-CD20 CAR T cells from melanoma patients within phase I clinical trial (NCT03893019). Using a second-generation lentiviral vector for the production of the CD20 CAR T cells on the CliniMACS Prodigy®.ResultsWe demonstrated consistency in cell composition and functionality of the products manufactured at two different production sites. The T cell purity was >98.5%, a CD4/CD8 ratio between 2.5 and 5.5 and transduction rate between 34% and 61% on day 12 (harvest). Median expansion rate was 53-fold (range, 42–65-fold) with 1.7-3.8×109 CAR T cells at harvest, a sufficient number for the planned dose escalation steps (1×105/kg, 1×106/kg, 1×107/kg BW). Complementary research of some of the products pointed out that the CAR+ cells expressed mainly central memory T-cell phenotype. All tested CAR T cell products were capable to translate into T cell activation upon engagement of CAR target cells, indicated by the increase in pro-inflammatory cytokine release and by the increase in CAR T cell amplification. Notably, there were some interindividual, cell-intrinsic differences at the level of cytokine release and amplification. CAR-mediated T cell activation depended on the level of CAR cognate antigen.DiscussionIn conclusion, the CliniMACS Prodigy® platform is well suited for decentralized POC manufacturing of anti-CD20 CAR T cells and may be likewise applicable for the rapid and automated manufacturing of CAR T cells directed against other targets.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT03893019?cond=Melanoma&term=NCT03893019&rank=1, identifier NCT03893019.
- Published
- 2024
- Full Text
- View/download PDF